progesterone induced blocking factor

You have access
New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor
JEROME H. CHECK and DIANE CHECK

Anticancer Research December 2021, 41 (12) 5873-5880; DOI: https://doi.org/10.21873/anticanres.15407
You have access
Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma
JEROME H. CHECK, DIANE CHECK, TRINA PORETTA and CARRIE WILSON

Anticancer Research April 2021, 41 (4) 2111-2115; DOI: https://doi.org/10.21873/anticanres.14982
You have access
Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life
JEROME H. CHECK, DIANE CHECK, MAYA D. SRIVASTAVA, TRINA PORETTA and JAMES K. AIKINS

Anticancer Research December 2020, 40 (12) 6997-7001; DOI: https://doi.org/10.21873/anticanres.14724
You have access
Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers – A Review
JEROME H. CHECK and DIANE CHECK

Anticancer Research July 2019, 39 (7) 3365-3372; DOI: https://doi.org/10.21873/anticanres.13479
You have access
Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor
JEROME H. CHECK, DIANE CHECK and TRINA PORETTA

Anticancer Research April 2019, 39 (4) 1923-1926; DOI: https://doi.org/10.21873/anticanres.13301

Main menu

User menu

Search

progesterone induced blocking factor